Press Release Archive

02.19.2013

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

01.31.2013

Pfizer Inc. Issues Statement on ZoetisTM IPO

01.30.2013

Pfizer Wins RAPAMUNE® Patent Case in Delaware District Court

01.28.2013

Pfizer Reports Fourth-Quarter and Full-Year 2012 Results; Provides 2013 Financial Guidance

01.25.2013

Pfizer Receives FDA Approval For The Use Of Prevnar 13 In Vaccine-Naive Children And Adolescents Aged 6 Years Through 17 Years For The Prevention Of Invasive Pneumococcal Disease

01.24.2013

ChapStick® Sessions Applies a Spotlight on Musically Talented Lips

01.23.2013

Study Shows Higher Dose Of Toviaz® (fesoterodine fumarate) Offers Greater Efficacy In Reducing Urge Urinary Incontinence In Patients With Overactive Bladder

01.23.2013

Pfizer Announces Top-Line Efficacy Results From A Phase 4 Study Of PRISTIQ® (desvenlafaxine) For The Treatment Of Major Depressive Disorder (MDD) In Adults

01.23.2013

CHANTIX® (varenicline) Demonstrates Efficacy in Smokers Who Previously Attempted to Quit Smoking with CHANTIX

01.21.2013

Pfizer Partnership Organizations Significantly Benefit From Pfizer’s Global Health Fellows Program

01.17.2013

Pfizer’s Bosutinib Receives Positive Opinion For Conditional Marketing Authorization From The Committee For Medicinal Products For Human Use For The Treatment Of Ph+ Chronic Myelogenous Leukemia With Resistance Or Intolerance To Prior Therapy In Europe

01.13.2013

Pfizer Announces Availability Of Quillivant XR™ (methylphenidate hydrochloride) CII For Extended-Release Oral Suspension In The United States